| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transplantation Conditioning | 63 | 2022 | 2358 | 3.460 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 43 | 2021 | 770 | 3.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 112 | 2024 | 6988 | 3.070 |
Why?
|
| Stem Cell Transplantation | 23 | 2021 | 1423 | 2.750 |
Why?
|
| Hodgkin Disease | 26 | 2022 | 1488 | 2.640 |
Why?
|
| Bone Marrow Transplantation | 33 | 2020 | 1772 | 2.350 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 23 | 2021 | 271 | 2.190 |
Why?
|
| Vidarabine | 32 | 2022 | 1383 | 2.150 |
Why?
|
| Anemia, Aplastic | 12 | 2018 | 233 | 2.060 |
Why?
|
| Transplantation, Homologous | 77 | 2024 | 3036 | 1.880 |
Why?
|
| Graft vs Host Disease | 67 | 2022 | 2804 | 1.820 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 17 | 2018 | 218 | 1.650 |
Why?
|
| Melphalan | 28 | 2019 | 875 | 1.600 |
Why?
|
| Tissue Donors | 17 | 2019 | 813 | 1.570 |
Why?
|
| Blood Donors | 17 | 2018 | 173 | 1.480 |
Why?
|
| Antilymphocyte Serum | 9 | 2017 | 237 | 1.060 |
Why?
|
| Unrelated Donors | 11 | 2021 | 321 | 1.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 56 | 2022 | 16628 | 0.980 |
Why?
|
| Myeloablative Agonists | 14 | 2021 | 386 | 0.970 |
Why?
|
| Leukapheresis | 15 | 2014 | 166 | 0.970 |
Why?
|
| Donor Selection | 4 | 2016 | 107 | 0.930 |
Why?
|
| Living Donors | 7 | 2018 | 178 | 0.920 |
Why?
|
| Cyclophosphamide | 18 | 2022 | 3243 | 0.920 |
Why?
|
| Graft vs Tumor Effect | 12 | 2012 | 143 | 0.910 |
Why?
|
| Immunosuppressive Agents | 20 | 2017 | 1443 | 0.910 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2015 | 1373 | 0.880 |
Why?
|
| Leukocyte Transfusion | 3 | 2012 | 44 | 0.760 |
Why?
|
| Transplantation, Autologous | 32 | 2022 | 2048 | 0.750 |
Why?
|
| Busulfan | 17 | 2022 | 786 | 0.750 |
Why?
|
| Filgrastim | 26 | 2014 | 194 | 0.740 |
Why?
|
| Blood Component Removal | 12 | 2012 | 121 | 0.730 |
Why?
|
| Recombinant Proteins | 34 | 2014 | 3071 | 0.720 |
Why?
|
| Antigens, CD34 | 15 | 2017 | 643 | 0.710 |
Why?
|
| Salvage Therapy | 15 | 2018 | 2122 | 0.700 |
Why?
|
| Adult | 149 | 2024 | 81993 | 0.690 |
Why?
|
| Recurrence | 40 | 2022 | 4887 | 0.670 |
Why?
|
| Peripheral Blood Stem Cells | 4 | 2021 | 9 | 0.670 |
Why?
|
| Middle Aged | 152 | 2024 | 90457 | 0.660 |
Why?
|
| Hematologic Neoplasms | 15 | 2022 | 1949 | 0.630 |
Why?
|
| Lymphoma | 11 | 2019 | 1514 | 0.560 |
Why?
|
| Deoxycytidine | 8 | 2018 | 1378 | 0.550 |
Why?
|
| Tissue and Organ Harvesting | 4 | 2018 | 127 | 0.550 |
Why?
|
| Adolescent | 72 | 2021 | 32759 | 0.530 |
Why?
|
| Humans | 209 | 2024 | 272039 | 0.520 |
Why?
|
| Male | 145 | 2024 | 129081 | 0.520 |
Why?
|
| Neutrophils | 7 | 2015 | 876 | 0.510 |
Why?
|
| Stem Cells | 6 | 2015 | 1236 | 0.490 |
Why?
|
| Female | 149 | 2024 | 149291 | 0.490 |
Why?
|
| Lymphocyte Transfusion | 5 | 2017 | 174 | 0.460 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2022 | 1736 | 0.460 |
Why?
|
| Aged | 95 | 2021 | 73500 | 0.460 |
Why?
|
| Disease-Free Survival | 41 | 2019 | 10258 | 0.440 |
Why?
|
| Remission Induction | 25 | 2016 | 3645 | 0.420 |
Why?
|
| Allografts | 10 | 2024 | 684 | 0.410 |
Why?
|
| Survival Rate | 35 | 2019 | 12547 | 0.410 |
Why?
|
| Rituximab | 14 | 2019 | 1588 | 0.410 |
Why?
|
| Multiple Myeloma | 13 | 2013 | 2287 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2022 | 7259 | 0.400 |
Why?
|
| Young Adult | 31 | 2021 | 22173 | 0.370 |
Why?
|
| Acute Disease | 18 | 2022 | 2510 | 0.360 |
Why?
|
| Photopheresis | 4 | 2021 | 79 | 0.360 |
Why?
|
| Leukemia | 9 | 2012 | 1721 | 0.320 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 | 2015 | 2635 | 0.320 |
Why?
|
| Aging | 2 | 2016 | 1578 | 0.320 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 15273 | 0.320 |
Why?
|
| Leukocyte Count | 12 | 2015 | 738 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 11 | 2014 | 3148 | 0.310 |
Why?
|
| Cytarabine | 14 | 2019 | 2014 | 0.300 |
Why?
|
| Immunoconjugates | 3 | 2016 | 314 | 0.300 |
Why?
|
| Histocompatibility Testing | 10 | 2018 | 485 | 0.300 |
Why?
|
| Graft Survival | 19 | 2018 | 1092 | 0.300 |
Why?
|
| Lymphoma, Non-Hodgkin | 7 | 2020 | 1068 | 0.300 |
Why?
|
| Leukemia, Myeloid | 5 | 2007 | 994 | 0.300 |
Why?
|
| Bone Marrow | 9 | 2021 | 2446 | 0.290 |
Why?
|
| Granulocytes | 1 | 2007 | 243 | 0.280 |
Why?
|
| Hematopoiesis | 5 | 2007 | 607 | 0.280 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2022 | 1839 | 0.280 |
Why?
|
| Treatment Outcome | 50 | 2018 | 33913 | 0.270 |
Why?
|
| Lymphoma, Follicular | 4 | 2021 | 636 | 0.260 |
Why?
|
| Survival Analysis | 20 | 2018 | 9318 | 0.260 |
Why?
|
| Cystitis | 2 | 2021 | 109 | 0.260 |
Why?
|
| Heterocyclic Compounds | 3 | 2015 | 119 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 10 | 2012 | 4496 | 0.240 |
Why?
|
| Child | 27 | 2018 | 30577 | 0.240 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2017 | 2474 | 0.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2003 | 426 | 0.240 |
Why?
|
| Pain | 6 | 2018 | 1698 | 0.240 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2015 | 382 | 0.240 |
Why?
|
| Combined Modality Therapy | 22 | 2019 | 9050 | 0.230 |
Why?
|
| Retrospective Studies | 40 | 2022 | 39828 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 9 | 2014 | 879 | 0.220 |
Why?
|
| Etoposide | 10 | 2018 | 905 | 0.210 |
Why?
|
| Lymphocyte Subsets | 4 | 2001 | 138 | 0.210 |
Why?
|
| Drug Administration Schedule | 10 | 2015 | 3537 | 0.210 |
Why?
|
| Lymphoma, T-Cell | 3 | 2015 | 369 | 0.210 |
Why?
|
| Tacrolimus | 8 | 2010 | 351 | 0.210 |
Why?
|
| Uveitis | 1 | 2002 | 39 | 0.200 |
Why?
|
| Antineoplastic Agents | 13 | 2013 | 14651 | 0.200 |
Why?
|
| Time Factors | 17 | 2021 | 13135 | 0.200 |
Why?
|
| Carmustine | 8 | 2019 | 224 | 0.200 |
Why?
|
| Bendamustine Hydrochloride | 3 | 2016 | 122 | 0.200 |
Why?
|
| Child, Preschool | 13 | 2016 | 17062 | 0.190 |
Why?
|
| Keratitis | 1 | 2002 | 125 | 0.190 |
Why?
|
| Blood Specimen Collection | 2 | 1999 | 97 | 0.190 |
Why?
|
| Blood Transfusion | 2 | 2008 | 584 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Guideline Adherence | 2 | 2015 | 645 | 0.190 |
Why?
|
| Graft Rejection | 6 | 2015 | 865 | 0.190 |
Why?
|
| Leukocytosis | 3 | 2014 | 115 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Risk Factors | 21 | 2018 | 18024 | 0.190 |
Why?
|
| Piperazines | 2 | 2009 | 2147 | 0.170 |
Why?
|
| Infectious Mononucleosis | 1 | 1999 | 38 | 0.170 |
Why?
|
| Prospective Studies | 14 | 2021 | 13404 | 0.170 |
Why?
|
| Antigens, CD | 5 | 2007 | 1435 | 0.170 |
Why?
|
| Bortezomib | 2 | 2019 | 542 | 0.160 |
Why?
|
| Age Factors | 7 | 2019 | 5519 | 0.160 |
Why?
|
| Neutropenia | 3 | 2002 | 1001 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 135 | 0.160 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 372 | 0.160 |
Why?
|
| Yttrium Radioisotopes | 2 | 2018 | 210 | 0.160 |
Why?
|
| Idarubicin | 3 | 2000 | 459 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2022 | 10369 | 0.160 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 3948 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2013 | 749 | 0.150 |
Why?
|
| Histocompatibility | 5 | 2018 | 183 | 0.150 |
Why?
|
| Siblings | 3 | 2022 | 313 | 0.150 |
Why?
|
| Prognosis | 20 | 2019 | 22543 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 3 | 2017 | 936 | 0.150 |
Why?
|
| Thrombocytopenia | 4 | 2010 | 872 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2016 | 5422 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2011 | 4964 | 0.140 |
Why?
|
| Infant | 5 | 2016 | 13984 | 0.140 |
Why?
|
| Nausea | 2 | 2016 | 540 | 0.140 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.140 |
Why?
|
| Fetal Blood | 2 | 2015 | 502 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 6275 | 0.140 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 311 | 0.140 |
Why?
|
| Safety | 4 | 2001 | 465 | 0.140 |
Why?
|
| Cell Count | 4 | 2021 | 524 | 0.130 |
Why?
|
| Pyrimidines | 2 | 2009 | 3664 | 0.130 |
Why?
|
| Hospitals, Special | 1 | 2015 | 25 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.130 |
Why?
|
| Hydroxamic Acids | 2 | 2016 | 455 | 0.130 |
Why?
|
| Blood Cells | 2 | 2009 | 130 | 0.130 |
Why?
|
| Blood Cell Count | 7 | 2012 | 234 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 2903 | 0.130 |
Why?
|
| Drug Therapy, Combination | 8 | 2022 | 2365 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 1995 | 53 | 0.120 |
Why?
|
| Whole-Body Irradiation | 3 | 2012 | 324 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| Accreditation | 1 | 2015 | 137 | 0.120 |
Why?
|
| Amebiasis | 1 | 1994 | 14 | 0.120 |
Why?
|
| Acanthamoeba | 1 | 1994 | 17 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 91 | 0.120 |
Why?
|
| Positron-Emission Tomography | 3 | 2008 | 2197 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 983 | 0.120 |
Why?
|
| Meningoencephalitis | 1 | 1994 | 28 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 1324 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 74 | 0.120 |
Why?
|
| Mucorales | 1 | 2014 | 31 | 0.120 |
Why?
|
| Ki-1 Antigen | 1 | 2015 | 186 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2008 | 2867 | 0.110 |
Why?
|
| Aspergillus | 1 | 2014 | 152 | 0.110 |
Why?
|
| Ifosfamide | 5 | 2011 | 357 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 58 | 0.110 |
Why?
|
| Steroids | 4 | 2021 | 375 | 0.110 |
Why?
|
| Mucormycosis | 1 | 2014 | 118 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 237 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2016 | 366 | 0.110 |
Why?
|
| Bone Marrow Diseases | 2 | 2012 | 187 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2014 | 637 | 0.100 |
Why?
|
| Oxides | 2 | 2014 | 212 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 5105 | 0.100 |
Why?
|
| Arsenicals | 2 | 2014 | 204 | 0.100 |
Why?
|
| Coinfection | 1 | 2014 | 202 | 0.100 |
Why?
|
| Aspergillosis | 1 | 2014 | 249 | 0.100 |
Why?
|
| Thrombopoietin | 2 | 2003 | 102 | 0.100 |
Why?
|
| Fatigue | 3 | 2012 | 1280 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 46 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1995 | 744 | 0.100 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 31071 | 0.100 |
Why?
|
| Transplantation Chimera | 4 | 2008 | 173 | 0.100 |
Why?
|
| Quality of Life | 2 | 2018 | 4758 | 0.100 |
Why?
|
| Interferon-alpha | 2 | 1996 | 964 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 1995 | 891 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1387 | 0.100 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 915 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2006 | 1732 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 685 | 0.090 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 441 | 0.090 |
Why?
|
| Monocytes | 2 | 2007 | 789 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 2674 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 2 | 2007 | 487 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 551 | 0.090 |
Why?
|
| Gallium Radioisotopes | 2 | 2008 | 62 | 0.090 |
Why?
|
| Pentostatin | 1 | 2010 | 121 | 0.090 |
Why?
|
| Chronic Disease | 7 | 2006 | 1850 | 0.090 |
Why?
|
| Platelet Count | 3 | 2017 | 491 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 684 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2016 | 757 | 0.090 |
Why?
|
| Neoplasms | 7 | 2022 | 15914 | 0.090 |
Why?
|
| Registries | 4 | 2010 | 2247 | 0.090 |
Why?
|
| Fever | 1 | 2012 | 516 | 0.080 |
Why?
|
| Heart | 1 | 1995 | 1211 | 0.080 |
Why?
|
| BK Virus | 1 | 2010 | 126 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2010 | 629 | 0.080 |
Why?
|
| Methotrexate | 5 | 2010 | 1033 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 1842 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 149 | 0.080 |
Why?
|
| Hospitals, University | 2 | 2008 | 220 | 0.080 |
Why?
|
| Thy-1 Antigens | 3 | 1997 | 52 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1439 | 0.080 |
Why?
|
| Benzylamines | 3 | 2015 | 101 | 0.080 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2008 | 39 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 249 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 425 | 0.080 |
Why?
|
| Cause of Death | 3 | 2018 | 785 | 0.080 |
Why?
|
| Hemostasis | 1 | 2009 | 99 | 0.080 |
Why?
|
| Thiotepa | 4 | 2006 | 132 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 131 | 0.080 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2007 | 33 | 0.080 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2009 | 107 | 0.070 |
Why?
|
| Feasibility Studies | 6 | 2015 | 2357 | 0.070 |
Why?
|
| Antigens, CD20 | 2 | 2006 | 207 | 0.070 |
Why?
|
| Incidence | 6 | 2020 | 5859 | 0.070 |
Why?
|
| CD3 Complex | 3 | 2004 | 321 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 2428 | 0.070 |
Why?
|
| Immune System | 1 | 2009 | 277 | 0.070 |
Why?
|
| Philadelphia Chromosome | 1 | 2011 | 836 | 0.070 |
Why?
|
| Vinblastine | 1 | 2008 | 462 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 908 | 0.070 |
Why?
|
| Headache | 2 | 1999 | 175 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2007 | 54 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2007 | 235 | 0.070 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2006 | 43 | 0.070 |
Why?
|
| Bleomycin | 1 | 2008 | 482 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 2 | 2001 | 235 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 609 | 0.070 |
Why?
|
| Autografts | 2 | 2018 | 179 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1996 | 217 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 355 | 0.070 |
Why?
|
| Body Weight | 3 | 2020 | 1335 | 0.070 |
Why?
|
| Retreatment | 2 | 2018 | 448 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2008 | 505 | 0.060 |
Why?
|
| Clinical Trials as Topic | 5 | 2011 | 3854 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 1153 | 0.060 |
Why?
|
| Thalidomide | 1 | 2009 | 595 | 0.060 |
Why?
|
| Antioxidants | 1 | 2008 | 522 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1996 | 316 | 0.060 |
Why?
|
| Skin | 2 | 2008 | 1284 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2008 | 1338 | 0.060 |
Why?
|
| Injections, Subcutaneous | 3 | 2014 | 344 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2008 | 1260 | 0.060 |
Why?
|
| Imatinib Mesylate | 2 | 2009 | 1690 | 0.060 |
Why?
|
| Thrombosis | 1 | 2010 | 754 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 13999 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2009 | 3146 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2010 | 835 | 0.060 |
Why?
|
| Benzamides | 2 | 2009 | 1882 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 2201 | 0.050 |
Why?
|
| Scleritis | 1 | 2002 | 11 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1056 | 0.050 |
Why?
|
| Podophyllotoxin | 2 | 2019 | 65 | 0.050 |
Why?
|
| Azacitidine | 2 | 2016 | 1220 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 214 | 0.050 |
Why?
|
| Heart Failure | 1 | 1995 | 2381 | 0.050 |
Why?
|
| Cladribine | 2 | 2001 | 253 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2006 | 151 | 0.050 |
Why?
|
| Encephalitis | 1 | 2003 | 154 | 0.050 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 583 | 0.050 |
Why?
|
| West Nile virus | 1 | 2003 | 132 | 0.050 |
Why?
|
| Cohort Studies | 6 | 2015 | 9484 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2012 | 124 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 2035 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2003 | 155 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Graft vs Host Reaction | 2 | 1998 | 62 | 0.050 |
Why?
|
| Transplantation, Haploidentical | 1 | 2022 | 159 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 1429 | 0.050 |
Why?
|
| Disease Progression | 5 | 2016 | 6909 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 311 | 0.050 |
Why?
|
| Texas | 1 | 2012 | 6433 | 0.050 |
Why?
|
| Breast Neoplasms | 7 | 2006 | 16252 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2004 | 954 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 168 | 0.040 |
Why?
|
| Cell Movement | 3 | 2015 | 2504 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2001 | 755 | 0.040 |
Why?
|
| Biopsy | 1 | 2008 | 3543 | 0.040 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 485 | 0.040 |
Why?
|
| Data Collection | 1 | 2002 | 624 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 2000 | 56 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 2012 | 1438 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 564 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2020 | 2251 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 184 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 499 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2022 | 457 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2009 | 1433 | 0.040 |
Why?
|
| Platelet Transfusion | 2 | 2015 | 168 | 0.040 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1999 | 159 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 216 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2011 | 4350 | 0.040 |
Why?
|
| Hospital Costs | 2 | 2001 | 250 | 0.040 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1998 | 38 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2010 | 747 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 4896 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2001 | 392 | 0.040 |
Why?
|
| Premedication | 1 | 2018 | 133 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 595 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1606 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3980 | 0.040 |
Why?
|
| Melanoma | 1 | 1995 | 5597 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2001 | 366 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 1106 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2017 | 85 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 4199 | 0.040 |
Why?
|
| Contraindications | 1 | 1997 | 155 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8627 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2001 | 1351 | 0.040 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2001 | 434 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1996 | 33 | 0.040 |
Why?
|
| Leukopenia | 1 | 1997 | 153 | 0.040 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1996 | 51 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 585 | 0.040 |
Why?
|
| Cell Separation | 1 | 1999 | 616 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 1728 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 253 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 7792 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1135 | 0.030 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1996 | 75 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 311 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1056 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 1483 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2014 | 6233 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 1996 | 253 | 0.030 |
Why?
|
| Liver | 2 | 2005 | 3123 | 0.030 |
Why?
|
| Logistic Models | 2 | 2009 | 3464 | 0.030 |
Why?
|
| Uric Acid | 1 | 1996 | 120 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 1996 | 168 | 0.030 |
Why?
|
| Survivors | 2 | 2014 | 1025 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 254 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 687 | 0.030 |
Why?
|
| Kinetics | 3 | 2006 | 2242 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Acinetobacter Infections | 1 | 1995 | 29 | 0.030 |
Why?
|
| Hemoglobins | 1 | 1996 | 485 | 0.030 |
Why?
|
| Mannans | 1 | 2014 | 31 | 0.030 |
Why?
|
| Galactose | 1 | 2014 | 79 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3395 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 660 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 1998 | 429 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 365 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2001 | 2289 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 177 | 0.030 |
Why?
|
| Stroke Volume | 1 | 1995 | 552 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 327 | 0.030 |
Why?
|
| Analgesics | 1 | 1996 | 410 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 251 | 0.030 |
Why?
|
| Convalescence | 1 | 2012 | 23 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 1393 | 0.030 |
Why?
|
| Arabinonucleosides | 1 | 2015 | 470 | 0.030 |
Why?
|
| Syncope | 1 | 2012 | 61 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 1995 | 405 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2009 | 1588 | 0.030 |
Why?
|
| HLA Antigens | 2 | 2009 | 589 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 355 | 0.030 |
Why?
|
| Spleen | 1 | 2014 | 731 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1996 | 969 | 0.020 |
Why?
|
| Tretinoin | 1 | 2014 | 622 | 0.020 |
Why?
|
| Social Class | 1 | 2013 | 322 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 595 | 0.020 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 35 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 718 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 128 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 150 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 656 | 0.020 |
Why?
|
| Consolidation Chemotherapy | 1 | 2012 | 154 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 5112 | 0.020 |
Why?
|
| United States | 3 | 2015 | 16033 | 0.020 |
Why?
|
| Brain | 2 | 2014 | 4257 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2417 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 28 | 0.020 |
Why?
|
| Hospital Bed Capacity | 1 | 2010 | 29 | 0.020 |
Why?
|
| Exanthema | 1 | 2012 | 210 | 0.020 |
Why?
|
| Sepsis | 1 | 1996 | 689 | 0.020 |
Why?
|
| Cross Infection | 1 | 1995 | 547 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2010 | 74 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2002 | 6882 | 0.020 |
Why?
|
| Physician Executives | 1 | 2010 | 45 | 0.020 |
Why?
|
| North America | 1 | 2010 | 342 | 0.020 |
Why?
|
| Topotecan | 1 | 2010 | 248 | 0.020 |
Why?
|
| Internationality | 1 | 2010 | 206 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2010 | 92 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2011 | 355 | 0.020 |
Why?
|
| Anesthesia | 1 | 2012 | 306 | 0.020 |
Why?
|
| Carcinoma | 1 | 2000 | 2623 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1621 | 0.020 |
Why?
|
| Heparin | 1 | 2010 | 346 | 0.020 |
Why?
|
| Patient Selection | 1 | 1996 | 2040 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2014 | 877 | 0.020 |
Why?
|
| Obesity | 2 | 2012 | 2944 | 0.020 |
Why?
|
| Pyrazines | 1 | 2011 | 511 | 0.020 |
Why?
|
| Immunologic Factors | 2 | 2006 | 669 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 879 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 617 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 499 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 147 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 114 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 729 | 0.020 |
Why?
|
| Syndecans | 1 | 2006 | 24 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2006 | 52 | 0.020 |
Why?
|
| Informed Consent | 1 | 2010 | 415 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4398 | 0.020 |
Why?
|
| Cryopreservation | 2 | 1999 | 171 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2007 | 103 | 0.020 |
Why?
|
| Family | 1 | 2010 | 779 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2006 | 278 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2006 | 201 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2672 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 225 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 1584 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 1064 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 615 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 4797 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 285 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2009 | 1509 | 0.010 |
Why?
|
| Infliximab | 1 | 2004 | 140 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2010 | 801 | 0.010 |
Why?
|
| Hospitalization | 1 | 2012 | 2183 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 3299 | 0.010 |
Why?
|
| Brimonidine Tartrate | 1 | 2002 | 6 | 0.010 |
Why?
|
| Acetazolamide | 1 | 2002 | 37 | 0.010 |
Why?
|
| Choroid Diseases | 1 | 2002 | 23 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 655 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 2002 | 182 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 369 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1266 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2001 | 88 | 0.010 |
Why?
|
| Quinoxalines | 1 | 2002 | 98 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2002 | 200 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 225 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2002 | 119 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 431 | 0.010 |
Why?
|
| Aerosols | 1 | 2001 | 149 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 4816 | 0.010 |
Why?
|
| Mesna | 1 | 2000 | 67 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 4002 | 0.010 |
Why?
|
| Ribavirin | 1 | 2001 | 177 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 520 | 0.010 |
Why?
|
| Mycoses | 1 | 2004 | 396 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 192 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2004 | 392 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2004 | 507 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 728 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2000 | 71 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 1460 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2472 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 1999 | 85 | 0.010 |
Why?
|
| Adenosine | 1 | 2001 | 300 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 10758 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 4993 | 0.010 |
Why?
|
| Probability | 1 | 1999 | 887 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 1668 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5941 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 2610 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 995 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2002 | 1230 | 0.010 |
Why?
|
| Harringtonines | 1 | 1996 | 93 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2171 | 0.010 |
Why?
|
| Equipment Design | 1 | 1999 | 1206 | 0.010 |
Why?
|
| Acinetobacter | 1 | 1995 | 12 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1995 | 134 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 221 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2001 | 1255 | 0.010 |
Why?
|
| Species Specificity | 1 | 1995 | 810 | 0.010 |
Why?
|
| Clone Cells | 1 | 1995 | 589 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 2001 | 708 | 0.010 |
Why?
|
| Alleles | 1 | 2000 | 2598 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 3512 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 5502 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 5330 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 1591 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 5213 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 6783 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1995 | 1071 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 1054 | 0.010 |
Why?
|
| Animals | 1 | 1994 | 62826 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1995 | 1659 | 0.000 |
Why?
|